Revenue Breakdown
Composition ()
No data
Revenue Streams
Urogen Pharma Ltd (URGN) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Jelmyto, accounting for 93.5% of total sales, equivalent to $25.70M. Another important revenue stream is Zusduri. Understanding this composition is critical for investors evaluating how URGN navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, Urogen Pharma Ltd maintains a gross margin of 88.07%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -99.65%, while the net margin is -121.34%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively URGN converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, URGN competes directly with industry leaders such as XERS and QURE. With a market capitalization of $1.02B, it holds a leading position in the sector. When comparing efficiency, URGN's gross margin of 88.07% stands against XERS's 81.57% and QURE's 89.25%. Such benchmarking helps identify whether Urogen Pharma Ltd is trading at a premium or discount relative to its financial performance.
